

No Protection against DSS-induced Colitis by Short-term Pretreatment with Seal or Fish Oils in Rats

Gülen Arslan^{1,6}, Kari Erichsen^{1,4}, Anne Marita Milde², Lars Helgeland⁵, Tormod Bjørkkjær^{3,6}, Livar Frøyland⁶ and Arnold Berstad^{1,4}

¹Institute of Medicine, ²Department of Biological and Medical Psychology, ³Department of Biomedicine, University of Bergen, and ⁴Department of Medicine and ⁵Department of Pathology, Haukeland University Hospital, and ⁶National Institute of Nutrition and Seafood Research (NIFES), Bergen, Norway.

Abstract

Background: Omega-3 (n-3) polyunsaturated fatty acids (PUFAs) have modulating effects in several chronic inflammatory conditions. The aim of the present study was to test whether prior short-term dietary supplementation with n-3 (fish or seal oil) or n-6 (soy oil) PUFA rich oils would protect the development of dextran sulfate sodium (DSS)-induced colitis in rats.

Methods: Forty-eight male Wistar rats were divided into 6 groups: no intervention, sham, DSS, seal oil + DSS, fish oil + DSS and soy oil + DSS. Following 7 days of acclimatisation, 1 mL oil (seal, fish or soy) or distilled water (sham) was administered by gavage day 8 to 14. Colitis was induced by 5% DSS in drinking water from day 15 to 21. Rats were sacrificed on day 23. Histological colitis (crypt and inflammation) scores, faecal granulocyte marker protein (GMP) and quantitative fatty acid composition in red blood cells were measured.

Results: Pretreatment with fish or seal oils did not significantly influence DSS induced inflammation. In fact, all the oils tended to exacerbate the inflammation. Soy oil increased the mean crypt score ($P < 0.04$), but not the inflammation score or GMP. The ratio of n-6 to n-3 fatty acids (FAs) was 11 to 1 and 10 to 1 in standard diet and in red blood cells of control rats, respectively. Following administration of DSS, the ratio fell in all treatment groups ($P < 0.001$). The lowest ratios were seen in the groups receiving DSS + fish or seal oils (around 6 to 1).

Conclusion: Short-term pretreatment with fish or seal oils did not protect against subsequent induction of colitis by DSS in this rat model. Whether the high ratio of n-6 to n-3 FAs in the standard diet concealed effects of n-3 FA supplementation should be further investigated.

Keywords: Colitis; dextran sulfate; seal oil; fish oil; soy oil; ratio omega-6 to omega-3; rats.

Introduction

Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn's disease (CD), is characterised by increased mucosal production of several eicosanoids, such as prostaglandin (PG) E₂, thromboxane A₂, prostacyclin I₂ and leukotriene (LT) B₄ (1). Recently, dietary supplementation with omega-3 (n-3) polyunsaturated fatty acids (PUFAs) to IBD patients has received considerable interest because these fatty acids (FAs) have the potential to modify eicosanoid production and inflammation. However, the results of clinical trials are equivocal (2, 3).

In some prior studies, increased dietary intakes of n-3 FAs led to biochemical, histological and clinical improvements, both in patients with IBD and in experimental models of colitis (4–6). In one animal model, even maternal dietary n-3 FA supplementation impaired the development of colitis in the offsprings (7). However, a recent retrospective multicenter case-control study reported that total fat and fat-related nutrients, including monounsaturated FAs and PUFAs, vitamin E, and n-3 and n-6 FAs increased the risk for IBD, particularly for CD (8).

Correspondence: Gülen Arslan, M.D., Ph.D., Department of Medicine, Section for Gastroenterology, Haukeland University Hospital, N-5021 Bergen, Norway. Tel: +47 93411359; Fax: +47 55974973; Email: gulen.arslan@med.uib.no

Please note that this article may not be used for commercial purposes. For further information please refer to the copyright statement at <http://www.la-press.com/copyright.htm>

The inhibited production of metabolites of arachidonic acid, especially products of the 5-lipoxygenase pathway, LTB_4 , is considered the most important mechanism by which n-3 FAs influence inflammation (9). The general rule is that eicosanoids derived from n-3 PUFAs are less potent triggers of immunological and inflammatory reactions, compared to the corresponding compounds derived from n-6 PUFAs. Hence, increased dietary intake of n-3 PUFAs may shift the balance of the eicosanoid production to a putatively less inflammatory profile, such as PGE_3 and LTB_5 . Both seal and fish oils are rich in n-3 PUFAs, but are different with respect to molecular localisation of the n-3 PUFAs on the triacylglycerol (TAG) molecule. N-3 PUFAs in seal oil are located almost exclusively at the end positions (*sn*-1 or *sn*-3 position) of the TAG molecule, whereas they are located mainly in the middle position (*sn*-2) of fish oil TAG (10, 11). During digestion and throughout the circulation, FAs are hydrolysed from the *sn*-1 and *sn*-3 positions by position specific pancreatic and lipoprotein lipases (12). The metabolism of structured TAGs is generally not influenced by different molecular localisation of n-3 PUFAs on TAG according to a recent review (13). However, it is not known whether effects of dietary TAGs on inflammatory and immunological reactions depend on molecular localization of n-3 PUFAs.

In man, incorporation of the fatty acids into cell membranes by oral administration of n-3 PUFA requires a long-term therapeutic strategy (14). Nevertheless, by duodenal administration, 10 days treatment with n-3 PUFA rich seal oil was enough to markedly alleviate joint pain in patients with IBD (15, 16). The intervention improved symptoms, fatty acid profile of red blood cells and rectal mucosa, and enhanced health related quality of life (17), but did not significantly change inflammation markers. In another double blind short-term (14-day) study using oral administration of seal oil and soy oil in psoriatic arthritis patients, we found no significant difference in symptomatic effects of the two oils (18). A major difference between the latter study in patients with psoriasis (18) and the prior studies in IBD-patients (15–17), was the mode of administration (oral versus duodenal).

Based on these short-term studies, we aimed to test whether prior short-term dietary supplementation with fish or seal oils (n-3 rich PUFAs), or soy oil (n-6 rich PUFAs) in addition to a background diet would influence the development of colonic

inflammation following subsequent exposure to dextran sulfate sodium (DSS) in rats. To our knowledge, this is the first study where the effect of seal oil on intestinal inflammation is investigated in an animal model.

Material and Methods

Animals

Forty-eight adult male Wistar rats (Møllegaard and Blomholtgaard, Ry, Denmark), with mean weight 371 g, were singly housed in Macrolon III cages. Access to food, Beekay rodent low protein diet consisting of cereal products (88,5%), soy protein (6%), animal proteins (2,5%), soy oil (0,5%) and vitamin-, mineral- and amino acid-supplementation (2,5%) (B&K Universal AS, Nittedal, Norway), was ad libitum. The nutrient and fatty acid composition of the standard diet is given in Table 1. Tap water was given ad libitum if not otherwise stated. Animals were maintained at controlled temperature ($21 \pm 1^\circ\text{C}$) with a 12 h light and 12 h dark cycle, relative humidity $55 \pm$

Table 1. Nutrients, energy and major fatty acids in the standard diet.

Moisture	8.00%
Crude oil	3.55%
Crude protein	14.59%
Crude fibre	5.02%
Ash	5.22%
NFE	63.62%
Dig. crude oil	2.67%
Dig. crude protein	12.32%
Pectin	1.50%
Hemicellulose	7.70%
Cellulose	4.05%
Lignin	1.05%
Starches	38.27%
Sugars	4.21%
Gross energy	14.91 MJ/kg
Dig. energy	12.84 MJ/kg
14:0	0.10%
16:0	0.64%
18:0	0.11%
16:1n-7	0.10%
18:1n-9	0.54%
18:2n-6	1.96%
18:3n-3	0.18%
n-6/n-3 ratio	10.9

NFE = nitrogen free extract. Dig = digestible, based on in-vitro digestibility analysis (according to manufacturer). Fatty acids given are % of crude oil. All data according to the product specification from manufacturer.

5% and 20 air changes per hour. The protocol was approved by the Norwegian Animal Research Authority.

Induction of DSS colitis

Acute colitis was induced by 50 g/L of DSS (MW 44 000, TdB Consultancy AB, Uppsala, Sweden) given in distilled drinking water for 7 successive days. The solution was refreshed every second day and consumption was accordingly measured.

Experimental design

Following 7 days (day 1–7) of acclimatisation (daily handling for 5 minutes by the same individuals), the 48 animals were randomly divided into 6 groups of 8; group 1: control (no intervention), group 2: sham (1 mL distilled water once daily by gavage day 8–21), group 3: DSS, group 4: soy oil + DSS, group 5: seal oil + DSS and group 6: fish oil + DSS. In the last three groups, first, oil was given by gavage for 7 days (day 8–14), and then the rats were exposed to DSS (day 15–21) without oil gavage. Gastric gavage was performed by using a feeding tube (CH 06, 50 cm, Maersk). Animals were held in the scruff of the neck and the feeding tube was placed into the stomach (around 8 cm from the tooth row).

The seal oil (Rieber Skinn A/S, Bergen, Norway) was a mixture of crude oil from harp seal (*Phagophilus groenlandicus*) and hooded seal (*Cystophora cristata*). The seal oil group received 0.07 g of eicosapentaenoic acid (EPA, 20:5n-3), 0.03 g of docosapentaenoic acid (DPA, 22:5n-3) and 0.07 g of docosahexaenoic acid (DHA, 22:6n-3), the fish oil group (cod liver oil, Peter Møller, Oslo, Norway) received 0.08 g of EPA, 0.01 g of DPA and 0.12 g of DHA, and the soy oil group (Mills DA, Oslo, Norway) received 0.5 g of linoleic acid (LA, 18:2n-6) and 0.06 g of α -linolenic acid (ALA, 18:3n-3) per day. The FA composition, levels of vitamin A and E and lipid peroxidation assessed by an in vitro method determining thiobarbituric acid reactive substances (TBARS) in the seal, fish and soy oils are presented in Table 2.

On day 23, all rats were anaesthetised by subcutaneous injection of a combination of fentanyl citrate + fluanisone (Hypnorm[®], Janssen Pharmaceutica, Beerse, Belgium) and midazolam (Dormicum[®], Roche, Oslo, Norway) (Fentanyl citrate 0.079 mg/mL, fluanisone 2.5 mg/mL, midazolam 1.25 mg/mL), at a dose of 0.2 mL/100g. Thoracotomy, cardiac puncture and exsanguination were performed.

Sample collection and analysis

Blood was drawn into a heparin-containing Vacutainer, placed on ice for 10 minutes and then centrifuged at 2000 rpm for 10 minutes at 4°C. Aliquots of red blood cells were stored at –80 °C for future analysis.

Quantitative FA composition was analysed in red blood cells (using biological sample parallels) and oils. The samples were dissolved in chloroform/methanol (2:1, w/w) and a 19:0 methyl ester was added as internal standard. The samples were filtered, saponified and methylated using 20% BF₃ in methanol. FA composition of total lipids was analysed using methods described by Lie and Lambertsen (19) where the methyl esters were separated using a Trace GC 2000 gas chromatograph (“cold on column” injection, 60²⁵ °C/min 160²⁵ °C/min 190²⁵ °C/min 220 °C), equipped with a 50 m CP-sil 88 (Chrompack) fused silica capillary column (id: 0.32 mm). The FAs were identified by retention time using standard mixtures of methylesters (Nu-Chek, Elyian, USA), and the quantitative FA composition was calculated using an integrator (Totalchrom), connected to the Gas Liquid Chromatography (GLC)-system.

Faeces were collected on day 22 and then stored at –20 °C until analysis of granulocyte marker protein (GMP), a marker of intestinal inflammation. Briefly, 1 g of faecal material was diluted in 4 mL extraction buffer and thoroughly homogenized using an Ultra Turrax (20,000 rpm) before centrifugation at 45000 g for 20 min. The upper halves of the supernatants were carefully harvested and ran on a standard one-step ELISA as described previously (20).

Tissue preparation and histological assessment

Colon from the colocecocal junction to the anal verge was removed for histological examination. The length of the colon was recorded. The colon was rinsed with phosphate-buffered saline buffer, opened longitudinally and divided into one proximal and one distal segment, which were fixed in 10% formalin and embedded in paraffin. Eight pieces per segment were stained with haematoxylin and eosin.

Colonic crypt and inflammatory scores were determined according to a validated scoring system (21), and examined by a pathologist unaware of the experimental protocol. Crypt injury was scored as; grade 0: intact crypts, grade 1: loss of bottom one

Table 2. Major fatty acids (g/100 g), vitamins A and E and TBARS.

	Seal oil	Fish oil	Soy oil
Σ saturated	12.9	15.4	13.4
16:1n-7	11.6	6.1	n.d
18:1n-9	16.3	13.7	17.5
20:1n-9	7.5	10.2	0.2
Σ monoenes	47.6	46.0	19.0
18:2n-6	1.4	1.5	49.7
20:4n-6	0.4	0.4	n.d
Σ ω-6	1.8	2.2	49.7
18:3n-3	0.7	0.8	5.5
20:5n-3	6.6	7.5	n.d
22:5n-3	3.1	1.1	n.d
22:6n-3	7.4	12.4	n.d
Σ ω-3	21.0	25.1	5.5
n-6/n-3	0.1	0.1	9.0
Sum vitamin A	1.4 mg/100g	4.8 mg/100g	n.d
α-tocopherol	5.4 mg/100g	309 mg/100g	17.1 mg/100g
TBARS	15.3 nmol/g WW	13.8 nmol/g WW	n.d

Sum vitamin A = all-trans retinol + 13-cis retinol + 3-Dehydroretinol.
 TBARS = thiobarbituric acid reactive substances. n.d = not detected.
 WW = wet weight.

third of crypts, grade 2: loss of bottom two thirds of crypts, grade 3: loss of entire crypt with the surface epithelium remaining intact, grade 4: loss of the entire crypt and surface epithelium. The severity of inflammation was scored as; grade 0: normal, grade 1: focal inflammatory cell infiltration, grade 2: inflammatory cell infiltration, gland dropout and crypt abscess. Both scores include a measure of involvement as follows; grade 1: 1–25%, grade 2: 26–50%, grade 3: 51–75%, grade 4: 76–100%. The score is the product of either the crypt or inflammation grade by the involvement grade. The final crypt and inflammation scores are the averages of all individual scores of 16 pieces per colon.

Statistical Analysis

Data were analysed using the GraphPad Prism version 4 (GraphPad Software Inc., USA) statistical software package. Results are presented as mean ± standard error of mean. Differences between means were evaluated with one-way ANOVA and Bonferroni post-test for selected pairs of columns. P values less than 0.05 were considered statistically significant.

Results

There were no significant differences in any parameter between the control (no intervention) group and

the sham group. These two groups were therefore merged into one group called controls in the presentation of results. One rat in the seal oil group bit off a piece of the distal part of the feeding tube on day 14, but the tube was visible at the upper part of larynx and was removed under isofluran anaesthesia. The experiment was completed without mortality.

DSS intake

Total intake of water with DSS was similar in the DSS group (157 ± 11.5 mL) and the oil + DSS groups (soy oil + DSS: 146 ± 14.2 mL; seal oil + DSS: 157 ± 10.7 mL and fish oil + DSS: 152 ± 8.1 mL).

Weight change

From the start of DSS treatment to sacrifice, weight loss was observed in all groups (DSS: -11.3 ± 4.0 g; soy oil + DSS: -7.6 ± 2.3 g; seal oil + DSS: -14.1 ± 4.2 g and fish oil + DSS: -23.4 ± 6.7 g), except in control rats (1.4 ± 1.9 g). Weight change did not significantly differ between controls and rats on DSS, or between groups receiving DSS and oils.

Colon length

Colon length did not significantly differ neither between controls (17.6 ± 0.4 cm) and DSS group (16.8 ± 0.4 cm) nor between DSS and oil + DSS groups

(soy oil + DSS: 16.3 ± 0.4 cm; seal oil + DSS: 16.1 ± 0.5 cm and fish oil + DSS: 15.4 ± 0.6 mL). However, there was a tendency to shorter colons in groups with colitis, especially in fish oil + DSS, as compared to controls.

Histology of the colon

Microscopic evaluation of colonic sections showed indications of colitis in all rats receiving DSS. Changes were most prominent in the distal colon with areas of erosions, crypt distortion and inflammatory cell infiltration as previously described (22) (Fig. 1). Soy oil significantly increased mean crypt score ($p < 0.04$), but not mean inflammation score, in rats with DSS-induced colitis. Such significant change was not seen in rats receiving n-3 FAs (seal or fish oil) + DSS (Fig. 2).

Granulocyte marker protein

After 7 days of DSS intake, faecal GMP levels increased significantly in rats on DSS (63.6 ± 19.5 mg/L) as compared with controls (7.8 ± 2.6 mg/L) ($p < 0.01$). There was no significant difference between DSS and oil + DSS groups. However, high faecal GMP levels were observed in rats receiving seal (84.8 ± 25.1 mg/L) and fish oils (88.5 ± 28.1 mg/L), but not soy oil (51.6 ± 14.9 mg/L).

Fatty acid composition

Compared with controls, there was a significantly lower n-6 to n-3 FA ratio in red blood cells of DSS and DSS + oil groups ($p < 0.001$) (Table 3).

Discussion

In the present study short-term pretreatment with either n-3 PUFA rich seal or fish oils as a supplement to an n-6 PUFA rich (soy based) standard diet did not protect against subsequent induction of colitis by DSS in rats. Contrary to what we hypothesized, the administration of all PUFAs tended to aggravate the inflammation. The oil-induced changes were not significant except for crypt injury score in the group receiving soy oil.


Based on the results from our previous studies (15–18), we expected a protective effect of short-term administration of n-3 PUFAs on the development of colonic inflammation. The lack of protection against colitis might be due to the short duration of oil supplementation (7 days) and the low dose of n-3 PUFAs given as a supplement to an n-6 PUFA rich standard diet. Other studies used at least 13 days oral administration or 2 weeks rectal enema (4, 11, 23) allowing the fatty acids to be incorporated into membranes. Such incorporation into red blood cells needs several weeks (14).

It is generally recommended that the human diet should return to a more balanced ratio of n-6 to n-3 FA (24). A ratio closer to 4 to 1 rather than the ratio of 20–15 to 1 as provided by current Western diet is supposed to be beneficial also for patients with IBD. An epidemiological study found increased intakes of n-6 FAs with a concomitant increase in the ratio of n-6 to n-3 FAs to be associated with increased occurrence of CD (25). A recent clinical study found reduced remission rates with increasing fat content when soy oil-based enteral feeds were administered to patients with active CD (26). Induction of colitis by DSS decreased the

Table 3. Fatty acid composition in red blood cells (mg/g) in study groups. Means (SEM).

<i>Fatty acid</i>	<i>Controls</i>	<i>DSS</i>	<i>Soy oil + DSS</i>	<i>Seal oil + DSS</i>	<i>Fish oil + DSS</i>
18:2 n-6	0.22 ± 0.03	0.22 ± 0.02	0.24 ± 0.01	0.24 ± 0.02	0.25 ± 0.02
20:3 n-6	0.01 ± 0.00	0.01 ± 0.00	0.01 ± 0.00	0.01 ± 0.00	0.01 ± 0.00
20:4 n-6	0.55 ± 0.07	0.57 ± 0.03	0.59 ± 0.02	0.52 ± 0.09	0.54 ± 0.02
Σ n-6	0.80 ± 0.07	0.79 ± 0.05	0.83 ± 0.02	0.78 ± 0.08	0.81 ± 0.03
18:3 n-3	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00
20:5 n-3	0.00 ± 0.00	0.00 ± 0.00	0.00 ± 0.00	0.01 ± 0.00	0.01 ± 0.00
22:5 n-3	0.03 ± 0.01	0.06 ± 0.10	0.03 ± 0.01	0.04 ± 0.01	0.04 ± 0.00
22:6 n-3	0.05 ± 0.01	0.06 ± 0.01	0.06 ± 0.01	0.07 ± 0.01	0.09 ± 0.01
Σ n-3	0.08 ± 0.01	0.12 ± 0.05	0.10 ± 0.01	0.13 ± 0.01	0.14 ± 0.00
n-6/n-3	10.0 ± 0.01	$6.6 \pm 0.05^*$	$8.3 \pm 0.01^*$	$6.0 \pm 0.02^*$	$5.8 \pm 0.00^*$

* indicates $p < 0.001$






Figure 1. H&E, 10X. **a)** Histologic appearance of the normal colonic mucosa of healthy control rat (intact crypts). **b)** Colonic mucosa of rat with DSS colitis showing crypt loss, inflammatory infiltration and crypt abscesses. **c)** Colonic mucosa of a rat which received soy oil and DSS. **d)** Colonic mucosa of a rat which received seal oil and DSS. **e)** Colonic mucosa of a rat which received fish oil and DSS (c, d and e show similar findings as in b).




Figure 2. Effect of DSS and n-3 or n-6 polyunsaturated fatty acids on histological crypt and inflammation scores. Results are expressed as mean $\pm$ SEM. Symbols mean significant difference, $p < 0.05$.

ratio of n-6 to n-3 FAs in all groups, possibly due to consumption of n-6 FAs for generation of pro-inflammatory prostaglandins and leukotriens. Even with n-3 PUFA rich seal or fish oils supplementation, the ratio remained high (around 6 to 1). Possibly due to the fact that the rats' standard diet had a high n-6 to n-3 FA ratio (11 to 1), both baseline (control groups) and final n-6 to n-3 ratios (experimental groups) were too high to disclose potential protective effects of n-3 PUFA rich oil supplementation.

DSS in the drinking water is a widely used experimental model of colitis (27). There are few studies testing effects of fish oil in DSS-induced colitis. Camuesco et al reported beneficial effects of adding fish oil to an olive oil diet (28). In another study, the effect of fish oil was compared with Lyprinol (Lipid extract of New Zealand Green Lipped Mussel) and olive oil in mice (23, 29). The results showed no significant benefit of fish oil compared with Lyprinol or olive oil. In our study, fish oil was richest in n-3 PUFAs and provided the lowest n-6 to n-3 ratio in blood, but still the fish oil + DSS group lost most weight, had the shortest colon and the highest GMP value (not significant). The level of α -tocopherol, added as an antioxidant for protection of PUFAs against lipid peroxidation, was in fact 57 times higher in the fish oil compared with the seal oil with quite similar TBARS values. Whether the crude seal oil contained additional beneficial substances compared with refined marine oils is not known. Amending regulations on contaminants prohibit the use of crude marine oils in clinical trials.

Faecal GMP, which corresponds to calprotectin in humans, has been used to monitor gut inflammation (30, 31). GMP extracted from faeces is a non-invasive marker of gastrointestinal inflammation in rats, and is derived from neutrophils and monocytes. In our study, exposure to 5% DSS induced histological inflammation, elevated faecal GMP concentration and loss of weight similar to that reported by others (27, 31). Treatment in all oil groups tended to aggravate the colitis, however, the change was significant in the soy oil group only. The significantly increased crypt injury score with soy oil might indicate a deleterious effect of soy oil because loss of crypts is a typical and early sign of DSS induced damage (32). Notably, while rats may convert ALA to EPA and DHA rather easily, humans can not. Relatively high ALA concentrations in soy oil may therefore mask deleterious effects of a high LA diet much more in rats than in humans (33). The oils were not oxidised according to TBARS measurement, and thus probably did not cause oxidative injury. Whether the use of a gastric gavage might have stressed the rats and thus contributed to the more severe colitis in the DSS + oil groups compared with DSS group is possible since stress is known to contribute to the severity of both experimentally induced colitis and ulcerative colitis (34). Control (no gavage) and sham (with gavage day 8–21) groups was however not different, but we have no additional sham + DSS group enabling us to conclude whether the oils per se or the gavage procedure per se, contributed to the development of colitis.

In conclusion, short-term pretreatment with seal or fish oils as a supplement to a n-6 PUFA rich (soy based) standard diet did not protect against subsequent induction of colitis by DSS in this rat model. Further studies are required to elucidate the effects of different n-6 to n-3 FA ratios in the diet and tissues before subsequent induction of colitis by DSS.

Acknowledgement

The study was funded by The Norwegian Fishermen Association, The Royal Ministry of Fisheries and Coastal Affairs, NIFES and Haukeland University Hospital. Georg Olsen and Annbjørg Bøkevoll are thanked for excellent analytical work. Oddrun Gudbrandsen and Hege Wergedahl are thanked for excellent technical work during the study. Rieber Skinn A/S supplied free samples of seal oil.

References

- [1] Whiting, C.V., Bland, P.W. and Tarlton, J.F. 2005. Dietary n-3 polyunsaturated fatty acids reduce disease and colonic proinflammatory cytokines in a mouse model of colitis. *Inflamm. Bowel. Dis.*, 11:340–349.
- [2] Belluzzi, A., Boschi, S., Brignola, C., Munarini, A., Cariani, G. and Miglio, F. 2000. Polyunsaturated fatty acids and inflammatory bowel disease. *Am. J. Clin. Nutr.*, Suppl 71:339S–342S.
- [3] Middleton, S.J., Naylor, S., Woolner, J. and Hunter, J.O. 2002. A double-blind, randomized, placebo-controlled trial of essential fatty acid supplementation in the maintenance of remission of ulcerative colitis. *Aliment. Pharmacol. Ther.*, 16:1131–1135.
- [4] Yüceyar, H., Özütemiz, O., Hüseyinov, A., Saruc, M., Alkanat, M., Bor, S., Coker, I. and Batur, Y. 1999. Is administration of n-3 fatty acids by mucosal enema protective against trinitrobenzene-induced colitis in rats. *Prostaglandins, Leukotrienes and Essential Fatty Acids*, 61:339–345.
- [5] Nieto, N., Torres, M.I., Rios, A. and Gil, A. 2002. Dietary polyunsaturated fatty acids improve histological and biochemical alterations in rats with experimental ulcerative colitis. *J. Nutr.*, 132:11–19.
- [6] Salomon, P., Kornbluth, A.A., Janowitz, H.D. 1990. Treatment of ulcerative colitis with fish oil n-3 fatty acid: an open trial. *J. Clin. Gastroenterol.*, 12:157–161.
- [7] Jacobsen, K., Mundra, H. and Innis, S.M. 2005. Intestinal responsiveness to experimental colitis in young rats is altered by maternal diet. *Am J Physiol Gastrointest Liver Physiol.*, 289:G13–G20.
- [8] Sakamoto, N., Kono, S., Wakai, K., Fukuda, Y., Satomi, M., Shimoyama, T., Inaba, Y., Miyake, Y., Sasaki, S., Okamoto, K., Kobashi, G., Washio, M., Yokoyama, T., Date, C. and Tanaka H. 2005. Dietary risk factors for inflammatory bowel disease. *Inflamm. Bowel. Dis.*, 11:154–163.
- [9] Barbosa, D.S., Cecchini, R., El Kadri, M.Z., Rodriguez, M.A.M., Burini, R.C. and Dichi, I. 2003. Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil n-3 fatty acids. *Nutrition*, 19:837–842.
- [10] Wanasundara, U. and Shahidi, F. 1997. Positional distribution of fatty acids in triacylglycerols of seal blubber oil. *J. Food. Lipids*, 4:51–64.
- [11] Yoshida, H., Kumamaru, J., Mawatari, M., Ikeda, I., Imaizumi, K., Tsuji, H. and Seto, A. 1996. Lymphatic absorption of seal and fish oils and their effect on lipid metabolism and eicosanoid production in rats. *Biosci. Biotechnol. Biochem.*, 60:1293–1298.
- [12] Small, D. 1991. The effects of glyceride structure on absorption and metabolism. *Ann. Review. Nutr.*, 11:413–434.
- [13] Mu, H., Porsgaard, T. 2005. The metabolism of structured triacylglycerols. *Prog. Lipid Res*, 44:430–448.
- [14] Von Schacky, C., Fisher, S. and Weber, P.C. 1985. Long-term effects of dietary marine n-3 fatty acids upon plasma and cellular lipids, platelet function and eicosanoid formation in humans. *J. Clin. Invest.*, 76:1626–31.
- [15] Arslan, G., Brunborg, L.A., Frøyland, L., Brun, J.G., Valen, M. and Berstad, A. 2002. Effects of duodenal seal oil administration in patients with inflammatory bowel disease. *Lipids*, 37:935–940.
- [16] Bjørkkjær, T., Brunborg, L.A., Arslan, G., Lind, R., Brun, J.G., Valen, M., Klementsén, B., Berstad, A. and Frøyland, L. 2004. Reduced joint pain after short-term duodenal administration of seal oil in patients with inflammatory bowel disease: comparison with soy oil. *Scand J Gastroenterol.*, 39:1088–1094.
- [17] Bjørkkjær, T., Brun, J.G., Valen, M., Arslan, G., Lind, R., Brunborg, L.A., Berstad, A. and Frøyland, L. 2006. Short-term duodenal seal oil administration normalised n-6 to n-3 fatty acid ratio in rectal mucosa and ameliorated bodily pain in patients with inflammatory bowel disease. *Lipids Health Dis.*, 5:6.
- [18] Madland, T.M., Bjørkkjær, T., Brunborg, L.A., Frøyland, L., Berstad, A. and Brun, J.G. 2006. Subjective improvement in patients with psoriatic arthritis after short-term oral treatment with seal oil. A pilot study with double blind comparison to soy oil. *J. Rheumatol.*, 33:307–310.
- [19] Lie, Ø. and Lambertsén, G. 1991. Fatty acid composition of Glycero-phospholipids in seven tissues of Cod (*Gadus morhua*), determined by Combined High-Performance Liquid Chromatography and Gas Chromatography. *J. Chromatography*, 565:119–129.
- [20] Erichsen, K., Milde, A.M., Arslan, G., Helgeland, L., Gudbrandsen, O., Ulvik, R.J., Berge, R.K., Hausken, T. and Berstad, A. 2005. Low dose oral ferrous fumarate aggravated intestinal inflammation in rats with DSS-induced colitis. *Inflamm. Bowel. Dis.*, 11:744–748.
- [21] Carrier, J., Aghdassi, E., Platt, I., Cullen, J. and Allard, J.P. 2001. Effect of oral iron supplementation on oxidative stress and colonic inflammation in rats with induced colitis. *Aliment. Pharmacol. Ther.*, 15:1989–1999.
- [22] Gaudio, E., Taddei, G. and Vetusch, A. 1999. Dextran sulfate sodium (DSS) colitis in rats: Clinical, structural, and ultrastructural aspects. *Dig. Dis. Sci.*, 144:1458–1475.
- [23] Tenikoff, D., Murphy, K.J., Le, M., Butler, R.N., Howarth, G.S. and Howe, P.R. 2004. Lyprinol (tm): a potential preventive treatment for inflammatory bowel disease (IBD)? *Asia. Pac. J. Clin. Nutr.*, Suppl 13: S94.
- [24] Kang, X.J., Wang, J., Wu, L. and Kang, Z.B. 2004. Fat-1 mice convert n-6 to n-3 fatty acids. *Nature*, 427:504.
- [25] Shoda, R., Matsueda, K., Yamato, S. and Umeda, N. 1996. Epidemiologic analysis of Crohn disease in Japan: Increased dietary intake of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. *Am. J. Clin. Nutr.*, 63:741–745.
- [26] Bamba, T., Shimoyama, T., Sasaki, M., Tsujikawa, T., Fukuda, Y. and Koganei, K. 2003. Dietary fat attenuates the benefits of an elemental diet in active Crohn's disease: a randomized, controlled trial. *Eur. J. Gastroent. Hepat.*, 15:151–157.
- [27] Venkatraman, A., Ramakrishna, B.S., Pulimood, A.B., Patra, S. and Murthy, S. 2000. Increased permeability in dextran sulphate colitis in rats: time course of development and effect of butyrate. *Scand. J. Gastroenterol.*, 35:1053–1059.
- [28] Camuesco, D., Galvez, J., Nieto, A., Comalada, M., Rodriguez-Cabezas, M.E., Concha, A., Xaus, J. and Zarzuelo, A. 2005. Dietary olive oil supplementation with fish oil, rich in EPA and DHA (n-3) polyunsaturated fatty acids, attenuates colonic inflammation in rats with DSS-induced colitis. *J. Nutr.*, 135:687–694.
- [29] Tenikoff, D., Murphy, K.J., Le, M., Butler, R.N., Howe, P.R. and Howarth, G.S. 2005. Lyprinol (stabilised extract of New Zealand green-lipped mussel): a potential preventative treatment modality for inflammatory bowel disease. *J. Gastroenterol.*, 40:361–365.

- [30] Berstad, A., Arslan, G. and Folvik, G. 2000. Relationship between intestinal permeability and calprotectin concentration in gut lavage fluid. *Scand. J. Gastroenterol.*, 35:64–69.
- [31] Milde, A.M., Arslan, G., Røseth, A., Berstad, A., Overmier, J.B., Murison, R. 2003. Intestinal permeability and faecal granulocyte marker protein in dextran sulphate sodium-induced colitis in rats. *Scand. J. Lab. Anim. Sci.*, 30:169–175.
- [32] Kitajima, O.S., Morimoto, M., Sagara, E., Shimizu, C., Ikeda, Y. 2001. Dextran sodium sulfate-induced colitis in germ-free IQI/Jic mice. *Exp. Anim.*, 50:387–395.
- [33] Burdge, G.C. and Calder, P.C. 2005. Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. *Reprod. Nutr. Dev.*, 45:581–597.
- [34] Collins, S.M. 2001. Stress and the Gastrointestinal Tract IV. Modulation of intestinal inflammation by stress: basic mechanisms and clinical relevance. *Am. J. Physiol. Gastrointestinal. Liver. Physiol.*, 280:G315–G318.